183 related articles for article (PubMed ID: 28826596)
1. Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.
Alwaseem H; Frisch BJ; Fasan R
Bioorg Med Chem; 2018 Apr; 26(7):1365-1373. PubMed ID: 28826596
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.
Kolev JN; O'Dwyer KM; Jordan CT; Fasan R
ACS Chem Biol; 2014 Jan; 9(1):164-73. PubMed ID: 24206617
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.
Tyagi V; Alwaseem H; O'Dwyer KM; Ponder J; Li QY; Jordan CT; Fasan R
Bioorg Med Chem; 2016 Sep; 24(17):3876-3886. PubMed ID: 27396927
[TBL] [Abstract][Full Text] [Related]
4. Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD).
Penthala NR; Balasubramaniam M; Dachavaram SS; Morris EJ; Bhat-Nakshatri P; Ponder J; Jordan CT; Nakshatri H; Crooks PA
Eur J Med Chem; 2021 Nov; 224():113675. PubMed ID: 34229108
[TBL] [Abstract][Full Text] [Related]
5. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells.
Bommagani S; Ponder J; Penthala NR; Janganati V; Jordan CT; Borrelli MJ; Crooks PA
Eur J Med Chem; 2017 Aug; 136():393-405. PubMed ID: 28525840
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-κB and STAT3 inhibitors.
Zeng B; Cheng Y; Zheng K; Liu S; Shen L; Hu J; Li Y; Pan X
Bioorg Chem; 2021 Jun; 111():104973. PubMed ID: 34004586
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.
Kempema AM; Widen JC; Hexum JK; Andrews TE; Wang D; Rathe SK; Meece FA; Noble KE; Sachs Z; Largaespada DA; Harki DA
Bioorg Med Chem; 2015 Aug; 23(15):4737-4745. PubMed ID: 26088334
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents.
Liu X; Wang X
Chin J Nat Med; 2022 Nov; 20(11):814-829. PubMed ID: 36427916
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization.
Alwaseem H; Giovani S; Crotti M; Welle K; Jordan CT; Ghaemmaghami S; Fasan R
ACS Cent Sci; 2021 May; 7(5):841-857. PubMed ID: 34079900
[TBL] [Abstract][Full Text] [Related]
10. The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation.
Schepetkin IA; Kirpotina LN; Mitchell PT; Kishkentaeva АS; Shaimerdenova ZR; Atazhanova GA; Adekenov SM; Quinn MT
Phytochemistry; 2018 Feb; 146():36-46. PubMed ID: 29216473
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic activity of aminoparthenolide analogs.
Nasim S; Crooks PA
Bioorg Med Chem Lett; 2008 Jul; 18(14):3870-3. PubMed ID: 18590961
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer activity of carbamate derivatives of melampomagnolide B.
Janganati V; Penthala NR; Madadi NR; Chen Z; Crooks PA
Bioorg Med Chem Lett; 2014 Aug; 24(15):3499-502. PubMed ID: 24928404
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells.
Yun BR; Lee MJ; Kim JH; Kim IH; Yu GR; Kim DG
Exp Mol Med; 2010 Nov; 42(11):787-97. PubMed ID: 20938215
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-acute myeloid leukemia activity of C-14 modified parthenolide derivatives.
Yang Z; Kuang B; Kang N; Ding Y; Ge W; Lian L; Gao Y; Wei Y; Chen Y; Zhang Q
Eur J Med Chem; 2017 Feb; 127():296-304. PubMed ID: 28068601
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of dual-action parthenolide prodrugs as potent anticancer agents.
Taleghani A; Nasseri MA; Iranshahi M
Bioorg Chem; 2017 Apr; 71():128-134. PubMed ID: 28215600
[TBL] [Abstract][Full Text] [Related]
16. Parthenolide: from plant shoots to cancer roots.
Ghantous A; Sinjab A; Herceg Z; Darwiche N
Drug Discov Today; 2013 Sep; 18(17-18):894-905. PubMed ID: 23688583
[TBL] [Abstract][Full Text] [Related]
17. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q
Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932
[TBL] [Abstract][Full Text] [Related]
19. Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)f NMR probes in deuterium-free environments.
Woods JR; Mo H; Bieberich AA; Alavanja T; Colby DA
J Med Chem; 2011 Nov; 54(22):7934-41. PubMed ID: 22029741
[TBL] [Abstract][Full Text] [Related]
20. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.
Albayati ZAF; Janganati V; Chen Z; Ponder J; Breen PJ; Jordan CT; Crooks PA
Bioorg Med Chem; 2017 Feb; 25(3):1235-1241. PubMed ID: 28049618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
